International Stem Cell Operating Income 2010-2024 | ISCO

International Stem Cell operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

International Stem Cell Operating Income 2010-2024 | ISCO

International Stem Cell operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158B
Bristol Myers Squibb (BMY)$119.2B
Vertex Pharmaceuticals (VRTX)$118.9B
Gilead Sciences (GILD)$112.8B
CSL (CSLLY)$88.8B
Regeneron Pharmaceuticals (REGN)$82.4B
GSK (GSK)$70.8B
Argenex SE (ARGX)$36.6B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$29B
Biogen (BIIB)$23.1B
Illumina (ILMN)$22.8B
BeiGene (BGNE)$18.5B
Moderna (MRNA)$16.8B
Incyte (INCY)$14.2B
Genmab (GMAB)$13.8B
Insmed (INSM)$13.3B
BioMarin Pharmaceutical (BMRN)$12.4B
Bio-Techne Corp (TECH)$11.8B
Vaxcyte (PCVX)$11.4B
Sarepta Therapeutics (SRPT)$11B
Exelixis (EXEL)$10.4B
Exact Sciences (EXAS)$10.2B
QIAGEN (QGEN)$9.9B
Revolution Medicines (RVMD)$9.7B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.1B
Intra-Cellular Therapies (ITCI)$9B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.9B